Magnetic resonance guidance is enough for prostate cancer: save adaptation for the patients it will really help
A partir d'une revue systématique de la littérature publiée entre 2018 et 2022 (29 études, 2 547 patients), cette méta-analyse évalue les toxicités liées à une radiothérapie stéréotaxique adaptative guidée par IRM par rapport aux radiochirurgies standard
Daily magnetic resonance (MR)-guided adaptive stereotactic body radiotherapy (SBRT) for prostate cancer will minimize grade 2 and worse toxicity compared with standard computed tomography-guided SBRT, but this is true for MR-guided SBRT without adaptation as well because the technology allows for smaller margins. Treating prostates with adaptive technology should not be performed at the expense of other patients who could benefit more from the technique and the technology.
Cancer , éditorial, 2022